Glucose-Derived Personalized HbA1c Correction (GDAC) Study to Improve Alignment Between CGM-Derived Metrics and HbA1c in Different Individuals and Racial Groups With Diabetes: Implications for Clinical Practice
Diabetes Care · 01.08.2026 · 49 (8) · 1420-1427
DOI: 10.2337/dc26-0398 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes Care, online erschienen am 08.06.2026. Verfasst von Ramzi A Ajjan und 3 weiteren Autor:innen. Beteiligte Einrichtung: The LIGHT Laboratories, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, U.K. Hauptthemen laut MEDLINE: Glycated Hemoglobin, Blood Glucose, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Abbott Diabetes Care.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE Glycated hemoglobin (HbA1c) and average glucose (AG) can show discordance due to personal variations in red blood cell (RBC) physiology, creating management difficulties. Our aims were to understand the size of the problem and refine this glycemic metric by adjusting for personal differences in RBC characteristics. RESEARCH AND DESIGN AND METHODS A 26-week prospective study was conducted in individuals with type 1 diabetes (T1D) or type 2 diabetes across four racial groups with HbA1c collected every 2 weeks and continuous glucose monitoring (CGM) used throughout. Personal glycation ratio (PGR) was derived from HbA1c and AG data (weeks 0–12), allowing calculation of personalized HbA1c (pA1C) and subsequent testing (weeks 20–26). The relationship between AG and HbA1c or pA1C was then analyzed, documenting a clinically meaningful discordance of ≥0.5%. In addition, we used real-world data sets to further validate the accuracy of pA1C at reflecting glucose exposure. RESULTS Of 257 participants (19% T1D) with complete CGM and HbA1c data sets, mean age (±SD) was 53 ± 14 years (45% females). The racial background was 35% Asian, 30% White, 22% Black, and 14% other/mixed. Of the total study population, 33% showed ≥0.5% HbA1c-AG discordance, with the Black population affected most (41% discordance). Use of pA1C reduced the discordance in the whole population to 14% (58% reduction), while this was reduced in the Black population to 12% (71% reduction). CONCLUSIONS HbA1c-AG discordance is common, particularly in the Black population, with pA1C improving alignment with glucose levels, potentially helping to optimize clinical management and reduce health disparities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The LIGHT Laboratories, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, U.K.
- Diabetes Research Centre, University of Leicester, Leicester, U.K.
- Clinical Affairs, Abbott Diabetes Care, Alameda, CA.
ORCID-Profile: Ramzi A Ajjan, Yongjin Xu, Timothy C Dunn
Förderung
- Abbott Diabetes Care
Zitieren
APA
Ajjan, R. A., Choudhary, P., Xu, Y., & Dunn, T. C. (2026). Glucose-Derived Personalized HbA1c Correction (GDAC) Study to Improve Alignment Between CGM-Derived Metrics and HbA1c in Different Individuals and Racial Groups With Diabetes: Implications for Clinical Practice. Diabetes Care, 49(8), 1420-1427. https://doi.org/10.2337/dc26-0398
Vancouver
Ajjan RA, Choudhary P, Xu Y, Dunn TC. Glucose-Derived Personalized HbA1c Correction (GDAC) Study to Improve Alignment Between CGM-Derived Metrics and HbA1c in Different Individuals and Racial Groups With Diabetes: Implications for Clinical Practice. Diabetes Care. 2026;49(8):1420-1427. doi:10.2337/dc26-0398
BibTeX
@article{Ajjan2026,
author = {Ajjan, Ramzi A and Choudhary, Pratik and Xu, Yongjin and Dunn, Timothy C},
title = {Glucose-Derived Personalized HbA1c Correction (GDAC) Study to Improve Alignment Between CGM-Derived Metrics and HbA1c in Different Individuals and Racial Groups With Diabetes: Implications for Clinical Practice},
journal = {Diabetes Care},
year = {2026},
volume = {49},
number = {8},
pages = {1420--1427},
doi = {10.2337/dc26-0398}
}
EUVIMED